Targeting Lipoprotein (a) to Understand its Impact on Atherosclerotic Cardiovascular
Disease

Susan      Hanson; Ishwarlal      Jialal
Keywords: Lipoproteins, atherosclerosis, lipoprotein (a), kringles, siRNA, anti-sense oligonucleotide, immunoassay, oxidized phospholipids.
[1]
Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol  2018; 71(2): 177-92.
 [http://dx.doi.org/10.1016/j.jacc.2017.11.014] [PMID: 29325642]

[2]
Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest  1987; 80(2): 458-65.
 [http://dx.doi.org/10.1172/JCI113093] [PMID: 2956279]

[3]
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol  2022; 42(1): e48-60.
 [http://dx.doi.org/10.1161/ATV.0000000000000147] [PMID: 34647487]

[4]
Forbes CA, Quek RGW, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: A systematic review. Lipids Health Dis  2016; 15(1): 95.
 [http://dx.doi.org/10.1186/s12944-016-0258-8] [PMID: 27184891]

[5]
Ehnholm C, Garoff H, Renkonen O, Simons K. Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. Biochemistry  1972; 11(17): 3229-32.
 [http://dx.doi.org/10.1021/bi00767a015] [PMID: 4340182]

[6]
Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett  1983; 154(2): 357-61.
 [http://dx.doi.org/10.1016/0014-5793(83)80182-3] [PMID: 6219896]

[7]
White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem  1994; 269(46): 28716-23.
 [http://dx.doi.org/10.1016/S0021-9258(19)61964-2] [PMID: 7961823]

[8]
Santonastaso A, Maggi M, De Jonge H, Scotti C. High resolution structure of human apolipoprotein (a) kringle IV type 2: Beyond the lysine binding site. J Lipid Res  2020; 61(12): 1687-96.
 [http://dx.doi.org/10.1194/jlr.RA120001023] [PMID: 32907988]

[9]
Kronenberg F. Human Genetics and the causal role of lipoprotein (a) for various diseases. Cardiovasc Drugs Ther  2016; 30(1): 87-100.
 [http://dx.doi.org/10.1007/s10557-016-6648-3] [PMID: 26896185]

[10]
Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]. Structural properties. J Biol Chem  1983; 258(7): 4582-9.
 [http://dx.doi.org/10.1016/S0021-9258(18)32663-2] [PMID: 6220008]

[11]
Koschinsky ML, Marcovina SM, May LF, Gabel BR. Analysis of the mechanism of lipoprotein(a) assembly. Clin Genet  1997; 52(5): 338-46.
 [http://dx.doi.org/10.1111/j.1399-0004.1997.tb04351.x] [PMID: 9520124]

[12]
Lim ET, Würtz P, Havulinna AS, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet  2014; 10(7): e1004494.
 [http://dx.doi.org/10.1371/journal.pgen.1004494] [PMID: 25078778]

[13]
Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci USA  1997; 94(22): 11992-7.
 [http://dx.doi.org/10.1073/pnas.94.22.11992] [PMID: 9342350]

[14]
Tsimikas S. Lipoprotein(a). Curr Opin Endocrinol Diabetes Obes  2016; 23(2): 157-64.
 [http://dx.doi.org/10.1097/MED.0000000000000237] [PMID: 26825471]

[15]
Martínez C, Rivera J, Loyau S, et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost  2001; 85(4): 686-93.
 [http://dx.doi.org/10.1055/s-0037-1615654] [PMID: 11341506]

[16]
Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease. JAMA Cardiol  2019; 4(12): 1287-95.
 [http://dx.doi.org/10.1001/jamacardio.2019.3780] [PMID: 31642874]

[17]
Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J  2019; 71(2): 99-112.
 [http://dx.doi.org/10.1016/j.ihj.2019.03.004] [PMID: 31280836]

[18]
Tsimikas S. A test in context: Lipoprotein(a). J Am Coll Cardiol  2017; 69(6): 692-711.
 [http://dx.doi.org/10.1016/j.jacc.2016.11.042] [PMID: 28183512]

[19]
Langsted A, Nordestgaard BG. Antisense oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep  2019; 21(8): 30.
 [http://dx.doi.org/10.1007/s11883-019-0792-8] [PMID: 31111240]

[20]
Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem  2021; 67(1): 154-66.
 [http://dx.doi.org/10.1093/clinchem/hvaa247] [PMID: 33236085]

[21]
Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Ann Clin Biochem  2021; 58(1): 16-21.
 [http://dx.doi.org/10.1177/0004563220968473] [PMID: 33040574]

[22]
Moriarty PM, Hemphill L. Lipoprotein apheresis. Endocrinol Metab Clin North Am  2016; 45(1): 39-54.
 [http://dx.doi.org/10.1016/j.ecl.2015.09.003] [PMID: 26892996]

[23]
ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT02791802. In: Bethesda (MD): US National Library of Medicine.  2000. Available from: http://clinicaltrials.gov/show/NCT00417417ClinicalTrials.gov

[24]
Swerdlow DI, Rider DA, Yavari A, Wikström Lindholm M, Campion GV, Nissen SE. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: The emerging potential of RNA interference therapeutics. Cardiovasc Res  2022; 118(5): 1218-31.
 [http://dx.doi.org/10.1093/cvr/cvab100] [PMID: 33769464]

[25]
Rider DA, Eisermann M, Löffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis  2022; S0021-9150(22): 00162-9.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2022.03.029]

[26]
Wittrup A, Lieberman J. Knocking down disease: A progress report on siRNA therapeutics. Nat Rev Genet  2015; 16(9): 543-52.
 [http://dx.doi.org/10.1038/nrg3978] [PMID: 26281785]

[27]
Hardy J, Niman S, Goldfaden RF, et al. A review of the clinical pharmacology of pelacarsen: A lipoprotein (a)-lowering agent. Am J Cardiovasc Drugs  2022; 22(1): 47-54.
 [http://dx.doi.org/10.1007/s40256-021-00499-1] [PMID: 34490591]

[28]
Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA  2022; 327(17): 1679-87.
 [http://dx.doi.org/10.1001/jama.2022.5050] [PMID: 35368052]

[29]
Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med  2022; 28(1): 96-103.
 [http://dx.doi.org/10.1038/s41591-021-01634-w] [PMID: 35027752]

[30]
O'Donoghue ML, López JA, Knusel B, et al. Study design and rationale for the OCEAN(a)-DOSE (olpasiran trials of cardiovascular events and LipoproteiN(a) reduction-DOSE finding study)trial. American Heart J 2022.

[31]
Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease. JAMA Cardiol  2022; 7(7): 760-9.
 [http://dx.doi.org/10.1001/jamacardio.2022.0987] [PMID: 35583875]

[32]
ClinicalTrials.gov. Identifier: NCT04023552. Rilonacept to improve artery function in patients with atherosclerosis. In: Bethesda (MD): US National Library of Medicine.  2000. Available from: http://clinicaltrials.gov/show/NCT00417417ClinicalTrials.gov
Cite As
Current Pharmaceutical Design

Targeting Lipoprotein (a) to Understand its Impact on Atherosclerotic Cardiovascular Disease
